
Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer
pharmafile | September 6, 2019 | News story | Medical Communications, Sales and Marketing | Cancer, Novartis, capmatinib, lung cancer, pharma
Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing the regulator’s coveted Breakthrough Therapy designation.
The pharma giant’s drug will now enter review as a first-line treatment of metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a rare mutated form which accounts for 3-4% of lung cancer cases.
The decision means that Novartis will be gearing up to take on Pfizer’s Xalkori, which also secured fast-track designation last year.
“We look forward to working with the FDA and global health authorities to bring capmatinib to patients who currently have no available targeted therapy options,” commented John Tsai, Novartis’s Chief Drug Developer.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cizzle Biotechnology expands US rollout of lung cancer blood test
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …






